My PROLASTIN®-C LIQUID
“I will not let alpha-1 stop me from living my best life.”
PROLASTIN-C LIQUID is the #1 prescribed augmentation therapy, trusted by alpha-1 patients and their doctors for more than 35 years.1
PROLASTIN-C LIQUID:
- An alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency)
- Raises alpha1 antitrypsin protein levels in patients with alpha1-antitrypsin deficiency (alpha-1)2
- Provides a concentrated form of the protein alpha1 antitrypsin, purified from human plasma
- Offers the convenience of receiving infusions at home, work, an infusion center, and even when traveling
What is PROLASTIN-C LIQUID?
Discover how PROLASTIN-C LIQUID works, how it is made, and what it can do for people with alpha-1.
Start the conversation with your doctor
Understanding how to treat your alpha-1 begins by talking with your doctor. Discover what’s important and how to share your concerns effectively.
You’re never alone
There is an entire community of alphas awaiting you. Access helpful resources for living with alpha-1 and information about treatment.
PROLASTIN-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Effects of PROLASTIN-C LIQUID on worsening lung function and emphysema progression have not been proven in clinical trials. Clinical data on the long term effects of augmentation therapy and maintenance therapy with PROLASTIN-C LIQUID are not available. PROLASTIN-C LIQUID is not meant to be used as a therapy for lung disease where severe alpha1-antitrypsin deficiency has not been established.
Heather and Toya, actual patients
What is alpha-1?
Alpha₁-antitrypsin deficiency is an underdiagnosed genetic disease. If you have alpha-1, your body does not make enough alpha₁ antitrypsin, a protein that protects the lungs from damage caused by inflammation and infections, and from environmental irritants like smoke or dust.3
What is life with PROLASTIN-C LIQUID like?
They’re alphas just like you, who understand what you’re going through. Get introduced to 3 patients receiving PROLASTIN-C LIQUID and learn about their treatment experiences.
Get help at every step of the journey with PROLASTIN DIRECT®
People with alpha-1 who are prescribed PROLASTIN-C LIQUID are automatically enrolled in PROLASTIN DIRECT, which helps patients navigate insurance, get started on treatment, and find ongoing support.
Join the PROLASTIN-C LIQUID community
Whether you’re receiving PROLASTIN-C LIQUID, you’re considering your treatment options, or you care for someone with alpha-1, you can receive helpful email updates about living with alpha-1 and treatment with PROLASTIN-C LIQUID.
Important Safety Information
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
References
- Data on file, Grifols.
- PROLASTIN-C LIQUID (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols.
- NIH National Heart, Lung, and Blood Institute. What is Alpha-1 Antitrypsin Deficiency?, www.nhlbi.nih.gov/health/alpha-1-antitrypsin-deficiency. Accessed 06 April 2025.